MAP LC3α activators encompass a range of compounds that indirectly enhance the functional activity of MAP LC3α, a key protein involved in the autophagic process. These activators primarily function by modulating pathways that regulate autophagy initiation and progression. Inhibitors of specific kinases known to negatively regulate autophagy can activate MAP LC3α by lifting the inhibition on this process, leading to the initiation of autophagy, where MAP LC3α plays a crucial role.
In addition to targeting kinase pathways, some activators influence the later stages of autophagy, such as autophagosome formation or autophagosome-lysosome fusion. These agents, by altering the autophagic flux, lead to changes in MAP LC3α activity as part of the cellular response to disrupted autophagy. Furthermore, compounds with known autophagy-inducing properties can enhance MAP LC3α activity by promoting the formation of autophagosomes. This complex regulation of autophagy and the pivotal role of MAP LC3α in this process underscore the importance of these activators in cellular homeostasis and stress response. Targeting different aspects of autophagy, from its initiation to completion, these activators offer insights into the modulation of key autophagic proteins and their implications in cellular health and disease.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a negative regulator of autophagy, potentially leading to the activation of MAP LC3α and autophagy initiation. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is a potent mTOR inhibitor, similar to Rapamycin, and can enhance autophagic processes, thereby activating MAP LC3α. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol can induce autophagy via multiple pathways, potentially leading to the activation of MAP LC3α. | ||||||
Spermidine | 124-20-9 | sc-215900 sc-215900B sc-215900A | 1 g 25 g 5 g | $57.00 $607.00 $176.00 | ||
Spermidine promotes autophagy through inhibition of the acetyltransferase EP300 and can activate MAP LC3α as part of this process. | ||||||
1,1-Dimethylbiguanide, Hydrochloride | 1115-70-4 | sc-202000F sc-202000A sc-202000B sc-202000C sc-202000D sc-202000E sc-202000 | 10 mg 5 g 10 g 50 g 100 g 250 g 1 g | $20.00 $43.00 $63.00 $156.00 $260.00 $510.00 $31.00 | 37 | |
1,1-Dimethylbiguanide, Hydrochloride activates AMPK, which can inhibit mTOR and subsequently activate MAP LC3α by promoting autophagy. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
3-MA inhibits autophagy at an early stage but can lead to compensatory mechanisms that activate MAP LC3α. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 inhibits the fusion between autophagosomes and lysosomes, potentially affecting MAP LC3α activity. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $57.00 | 1 | |
Hydroxychloroquine, similar to Chloroquine, can affect autophagic flux and influence MAP LC3α activity. | ||||||
D-(+)-Trehalose Anhydrous | 99-20-7 | sc-294151 sc-294151A sc-294151B | 1 g 25 g 100 g | $30.00 $167.00 $260.00 | 2 | |
Trehalose induces autophagy and can lead to the activation of MAP LC3α through this mechanism. | ||||||
Lys05 | 1391426-24-6 | sc-507532 | 5 mg | $140.00 | ||
Lys05 is a dimeric Chloroquine derivative that inhibits autophagosome-lysosome fusion, affecting MAP LC3α levels. | ||||||